Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination.

ABSTRACT:

Objective

The pandemic induced by SARS-CoV-2 has huge implications for patients with immunosuppression that is caused by disorders or specific treatments. Especially approaches targeting B cells via anti-CD20 therapy are associated with impaired humoral immune response but sustained cellular immunity. Ofatumumab is a human anti-CD20 directed antibody applied in low dosages subcutaneously, recently licensed for Multiple Sclerosis (MS). Effects of early ofatumumab treatment on alterations of immune cell composition and immune response towards SARS-CoV-2 are incompletely understood.

Methods

We here investigated immune cell alterations in early ofatumumab (Ofa) treated patients and effects on humoral (titer, neutralization capacity against wild type, Delta and Omicron) an

SUBMITTER: Faissner S 

PROVIDER: S-EPMC9471319 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature